See more : ESAF Small Finance Bank (ESAFSFB.NS) Income Statement Analysis – Financial Results
Complete financial analysis of VistaGen Therapeutics, Inc. (VTGN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of VistaGen Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dilip Buildcon Limited (DBL.BO) Income Statement Analysis – Financial Results
- Andretti Acquisition Corp. II (POLEW) Income Statement Analysis – Financial Results
- Puda Coal, Inc. (PUDA) Income Statement Analysis – Financial Results
- Tower Resources Ltd. (TWRFF) Income Statement Analysis – Financial Results
- Snap-on Incorporated (SNA) Income Statement Analysis – Financial Results
VistaGen Therapeutics, Inc. (VTGN)
About VistaGen Therapeutics, Inc.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 200.40K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 103.10K | 91.20K | 80.70K | 0.00 | 53.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | 0.00 | 0.00 | 1.25M | 0.00 | 0.00 | 0.00 | 200.40K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 20.02M | 44.38M | 35.41M | 11.93M | 13.37M | 17.10M | 7.76M | 5.20M | 3.93M | 2.43M | 2.48M | 3.43M | 5.39M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 14.06M | 14.66M | 10.45M | 7.10M | 6.60M | 7.43M | 6.44M | 5.87M | 13.92M | 4.25M | 2.55M | 3.56M | 4.36M | 8.39K | 21.54K | 16.35K | 4.78K |
| Selling & Marketing | 0.00 | 1.90M | 2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 128.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.06M | 14.66M | 13.25M | 7.10M | 6.60M | 7.43M | 6.44M | 5.87M | 13.92M | 4.25M | 2.55M | 3.56M | 4.36M | 8.52K | 21.54K | 16.35K | 4.78K |
| Other Expenses | 0.00 | 0.00 | 232.00K | -400.00 | -827.00K | -48.70K | -428.00K | 426.80K | -2.30K | -233.00K | 0.00 | 0.00 | 641.00K | 428.00 | 428.00 | 36.00 | 0.00 |
| Operating Expenses | 34.09M | 59.04M | 48.89M | 19.02M | 19.97M | 24.53M | 14.20M | 11.50M | 17.85M | 6.68M | 5.03M | 6.99M | 10.39M | 8.95K | 21.97K | 16.39K | 4.78K |
| Cost & Expenses | 34.09M | 59.04M | 48.89M | 19.02M | 19.97M | 24.53M | 14.20M | 11.50M | 17.85M | 6.68M | 5.03M | 6.99M | 10.39M | 8.95K | 21.97K | 16.39K | 4.78K |
| Interest Income | 0.00 | 49.00K | 20.00K | 15.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 5.00K | 10.00K | 30.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 23.00K | 0.00 | 13.00K | 15.00K | 8.00K | 8.90K | 5.00K | 777.00K | 4.62M | 1.56M | 1.00M | 1.89M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 568.00K | 532.00K | 711.10K | 477.60K | 103.10K | 91.20K | 80.70K | 54.90K | 53.50K | 59.10K | 54.60K | 33.80K | 45.60K | 428.00 | 428.00 | 36.00 | 0.00 |
| EBITDA | -32.45M | -58.74M | -47.05M | -17.44M | -20.65M | -24.47M | -14.25M | -9.77M | -17.80M | -6.72M | -4.97M | -11.85M | -10.27M | -6.32M | -21.54K | -16.35K | -4.78K |
| EBITDA Ratio | -3,050.09% | 25,816.45% | -4,221.83% | -1,633.87% | 0.00% | 0.00% | 0.00% | -815.46% | 0.00% | 0.00% | 0.00% | -3,340.62% | -670.38% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -33.02M | -59.27M | -47.78M | -17.93M | -20.80M | -24.56M | -14.20M | -10.25M | -17.85M | -6.78M | -5.03M | -6.79M | -9.04M | -8.95K | -21.97K | -16.39K | -4.78K |
| Operating Income Ratio | -3,103.48% | 26,040.74% | -4,308.68% | -1,646.06% | 0.00% | 0.00% | 0.00% | -819.88% | 0.00% | 0.00% | 0.00% | -3,389.77% | -673.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.66M | 26.00K | 19.90K | 2.20K | 30.10K | -30.70K | -143.90K | -4.60K | -29.37M | -7.11M | 2.06M | -6.09M | -3.16M | -9.47M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -29.36M | -59.24M | -47.76M | -17.93M | -20.77M | -24.59M | -14.34M | -10.25M | -47.22M | -13.88M | -2.97M | -12.88M | -12.21M | -8.95K | -21.97K | -16.39K | -4.78K |
| Income Before Tax Ratio | -2,759.21% | 26,063.26% | -4,306.88% | -1,645.86% | 0.00% | 0.00% | 0.00% | -820.25% | 0.00% | 0.00% | 0.00% | -6,428.64% | -909.54% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 4.00K | 6.00K | 3.40K | 2.60K | 2.60K | 2.60K | 2.40K | 2.40K | 2.30K | 2.40K | 2.70K | 3.70K | 1.60K | 30.00 | 30.00 | 30.00 | -30.00 |
| Net Income | -29.36M | -59.25M | -47.76M | -17.93M | -20.77M | -24.59M | -14.35M | -10.26M | -47.22M | -13.89M | -2.97M | -12.89M | -12.21M | -8.98K | -22.00K | -16.42K | -4.75K |
| Net Income Ratio | -2,759.59% | 26,065.86% | -4,307.19% | -1,646.09% | 0.00% | 0.00% | 0.00% | -820.44% | 0.00% | 0.00% | 0.00% | -6,430.49% | -909.66% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.28 | -318.27 | -74.47 | -426.99 | -497.11 | -0.46 | -1.13 | -0.95 | -0.28 |
| EPS Diluted | -1.52 | -8.51 | -7.24 | -6.25 | -14.21 | -25.83 | -30.98 | -40.85 | -801.27 | -315.87 | -81.00 | -426.98 | -497.11 | -0.46 | -1.13 | -0.95 | -0.28 |
| Weighted Avg Shares Out | 19.35M | 6.96M | 6.60M | 2.87M | 1.46M | 952.08K | 463.00K | 251.05K | 58.93K | 43.63K | 39.85K | 30.18K | 24.56K | 19.50K | 19.50K | 17.34K | 17.00K |
| Weighted Avg Shares Out (Dil) | 19.35M | 6.96M | 6.60M | 2.87M | 1.46M | 952.08K | 463.00K | 251.05K | 58.93K | 43.96K | 36.64K | 30.18K | 24.56K | 19.50K | 19.50K | 17.34K | 17.00K |
Vistagen Announces Pricing of $100 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen Therapeutics, Inc. (“Vistagen”) (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (“CNS”) disorders, today announced the pricing...
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
The best short-squeeze stocks to buy now can be a perilous territory in the investment landscape. However, they also possess the potential for astronomical returns.
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the...
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen's Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan
SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)---- $VTGN #menopause--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Fuji Pharma Co., Ltd. (“Fuji”)...
Vistagen Appoints Cindy Anderson as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson...
Vistagen Therapeutics, Inc. (VTGN) Q1 2024 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Mark Flather - VP of IR Shawn Singh - CEO Josh Prince - SVP of Business Operations Conference Call Participants Andrew Tsai...
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported...
Outperforming Biotech Pops on Shareholder Buzz
Vistagen Therapeutics Inc (NASDAQ:VTGN) is continuing its recent volatility, after today's news that healthcare investment name Commodore Capital Master LP has become a top shareholder with a 19.7% stake.
Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VTGN #mentalhealth--Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference...
Why Is Vistagen Therapeutics (VTGN) Stock Up 650% Today?
Vistagen Therapeutics (NASDAQ: VTGN ) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into penny stock status and coming dangerously close to the $1 per...
Source: https://incomestatements.info
Category: Stock Reports